| 학회 | 한국고분자학회 |
| 학술대회 | 2005년 봄 (04/14 ~ 04/15, 전경련회관) |
| 권호 | 30권 1호, p.89 |
| 발표분야 | 유ㆍ무기 나노섬유 소재 |
| 제목 | Electrospun biodegradable nanofibers for the delivery of drug and DNA |
| 초록 | Within the last decade, numerous studies have demonstrated the use of biodegradable polyesters and their copolymers, such as poly(lactide)(PLA), poly(lactide-co-glycolide) (PLGA), poly(lactide-b-ethylene glycol)(PLA-b-PEG), as effective carriers for drug (or DNA/protein) delivery.1-5 These drug carriers, can be classified into four categories: (1) nano- or micro-particles, (2) hydrogels, (3) micelles and (4) fibrous membranes, each with certain advantages and disadvantages. Especially, electrospun nanofibrous membrane has a potential, such as large surface area and high porosity as well as flexibility for the delivery of drug or DNA. Moreover, the release profile of drug or DNA can be finely controlled by the modulation of the membrane’s morphology, porosity and composition. The main advantage of this system is that it offers site-specific delivery of any number of drugs from the membrane into the body.6 In this study, PLGA blend solutions with different drug (or DNA) concentrations were electrospun to fabricate nanofibrous membranes, and the release profile of drug (or DNA) from the membrane was investigated in in-vitro condition. Successful incorporation and sustained release of a hydrophilic antibiotic drug (cefoxitin sodium) or DNA from the electrospun PLGA based membranes were demonstrated without the loss of structure or bioactivity. The introduction of an amphiphilic block copolymer (PLA-b-PEG) in PLGA reduced the cumulative amount of the released drug at earlier time points, and prolonged the drug release at longer times (up to a one-week period). Also, the block copolymer in DNA delivery vastly affected both the rate and the efficiency of DNA release. Fig. 1. The drug (cefoxitin sodium) release profiles from medicated electrospun scaffolds. The data represent the mean S.D. (n=5 scaffolds): (a) medicated PLGA with 1 wt% drug, (b) medicated PLGA/PLA/PLA-b-PEG blend with 5 wt% drug, and (c) medicated PLGA with 5 wt% drug. References 1. R. Langer, Science 249, 1527 (1990). 2. E.H. Sanders, R. Kloefkorn, G.L. Bowlin, D.G. Simpson, G.E. Wnek, Macromolecules, 36, 3803 (2003). 3. K. Kim, C. Chang, Y. K. Luu, D. Fang, B. S. Hsiao, B. Chu, and M. Hadjiargyrou, J. Control. Release, 98, 47 (2004). 4. K. Kim, M. Yu, X. Zong, J. Chiu, D. Fang, Y. S. Seo, B. S. Hsiao, B. Chu, and M. Hadjiargyrou, Biomaterials , 24, 4977 (2003). 5. Yen. Kim Luu, K. Kim, Benjamin S. Hsiao, Benjamin Chu, and Michael Hadjiargyrou, J. Control. Release, 89, 341 (2003). 6. X. Zong, S. Li, E. Chen, B. Garlick , K. Kim, D. Fang, J. Chiu, T. Zimmerman, C. Brathwaite, B.S.Hsiao, B.Chu, Annals of Surgery, 240, 910 (2004). |
| 저자 | 김광석, 진인주, 최형진 |
| 소속 | 인하대 |
| 키워드 | electrospinning; nanofibrous membrane; drug (or DNA) delivery; PLGA; PLA-b-PEG |
